Brenzavvy (bexagliflozin) / TheracosBio - LARVOL DELTA

Comparison chart: Sodium-glucose cotransporter 2 (SGLT2) inhibitors. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Noninsulin drugs for type 2 diabetes. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Rationale and design of the Adipose Dysfunction, Imaging, Physiology, and Outcomes with sodium-glucose cotransporter - 2 inhibitors for Sleep Apnea (ADIPOSA) study. (PubMed, Contemp Clin Trials) - "The ADIPOSA study will identify the mechanisms underlying the effects of SGLT2i on OSA while providing evidence for future investigation to test the efficacy of pharmacologic SGLT2i on OSA prevention and treatment."

Clinical • Journal • CNS Disorders • Diabetes • Genetic Disorders • Inflammation • Metabolic Disorders • Obesity • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Apnea • Sleep Disorder

Clinical therapeutics in feline medicine: updates for old and new drugs. (PubMed, J Feline Med Surg) - "The clinical use of these agents, available pharmacokinetic and pharmacodynamic data, and reported adverse effects in cats are presented. The information in this article is relevant to all veterinarians who practice feline medicine."

Journal • Review

Efficacy and Safety of Non-Insulin Antidiabetic Drugs in Cats: A Systematic Review. (PubMed, Animals (Basel)) - "The evidence supports a paradigm shift towards SGLT2 inhibitors as a viable oral monotherapy for select cases of FDM. This alters the clinical risk-benefit discussion from preventing hypoglycemia to mitigating eDKA. Significant evidence gaps remain, particularly the lack of high-quality RCTs and data in cats with common comorbidities."

Journal • Review • Amyloidosis • Diabetes • Hypoglycemia • Metabolic Disorders

Cycloadditions as a Sweet Route to 'Double C-Glycosylation'. (PubMed, Biomolecules) - "Pharmaceuticals, such as the antibiotic erythromycin, and sodium-dependent glucose transporter (SGLT1 & SGTL2) inhibitors such as Bexagliflozin (diabetes) and Sotagliflozin (heart disease), are often sugar-decorated (glycosylated). The way in which this "double C-glycosylation" is naturally mediated is not yet known, yet has been speculated on. Here, we report the exploration and development of a potentially biomimetic procedure that utilises intermolecular cycloaddition chemistry to access new "double C-glycosylated" products and enables the creation of bridged polycyclic ethers from a common maltol-derived oxidopyrylium salt precursor."

Journal • Cardiovascular • Diabetes • Heart Failure • Metabolic Disorders

Bexagliflozin on Renal Outcomes in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. (PubMed, Cureus) - "However, there was a significant reduction in systolic blood pressure in the treatment group (MD: -4.2 mmHg; 95% CI: -5.6 to -2.8; p < 0.01). In large placebo-controlled trials, we observed no beneficial effect of bexagliflozin on kidney function, as described with other SGLT2 inhibitors."

Journal • Retrospective data • Review • Diabetes • Diabetic Nephropathy • Metabolic Disorders • Type 2 Diabetes Mellitus

Clinical efficacy and safety of sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor, glucagon-like peptide-1 (GLP-1) receptor agonist, and Finerenone in type 2 diabetes mellitus with non-dialysis chronic kidney disease: a network meta-analysis of randomized clinical trials. (PubMed, Front Pharmacol) - "According to the SUCRA based relative ranking of treatments, Empagliflozin was the most effective in reducing HbA1c and DBP...Liraglutide was the most effective in reducing LDL-C. Bexagliflozin, Canagliflozin were the most effective in reducing SBP and body weight. Finerenone had the lowest incidence of urinary tract infection, Hypoglycemia was the lowest in the Luseogliflozin group. Ertugliflozin was the least likely to cause acute kidney injury...SGLT-2 inhibitors had a preferential glucose-lowering and weight-loss function, GLP-1 receptor agonists had a preferential lowering of LDL-C and blood glucose, and Finereone significantly reduced SBP compared with PBO. Systematic Review Registration: PROSPERO, CRD42024571544."

Clinical • Journal • Retrospective data • Review • Acute Kidney Injury • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Dyslipidemia • Hypoglycemia • Infectious Disease • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Sodium-glucose co-transporter 2 inhibitors: a pleiotropic drug in humans with promising results in cats. (PubMed, Front Vet Sci) - "We also review the available literature regarding other benefits of these drugs in humans as well as the effects of SGLT2i in cats. Adverse effects related to the use of these hypoglycemic drugs are also discussed."

Journal • Review • Cardiovascular • Cognitive Disorders • Diabetes • Heart Failure • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

A renal indication for semaglutide (Ozempic). (PubMed, Med Lett Drugs Ther) - No abstract available

Journal

Redefining outcomes of ventricular arrhythmia for SGLT2 inhibitor medication in heart failure patients: a meta-analysis of randomized controlled trials. (PubMed, Syst Rev) - "SGLT2 inhibitors have beneficial effects on lowering risks of VAs and SCD in patients with type 2 diabetes, cardiovascular diseases, heart failure with reduced ejection fraction (HFrEF), heart failure with preserved ejection fraction (HFpEF), and heart failure with mildly reduced ejection fraction (HFmrEF), with longer follow-up duration reinforcing these findings. However, future prospective trials are needed to verify the effects of SGLT2 inhibitors on VAs and SCD."

Clinical • Journal • Retrospective data • Review • Cardiovascular • Congestive Heart Failure • Diabetes • Heart Failure • Metabolic Disorders • Type 2 Diabetes Mellitus

Novel FDA-approved bexagliflozin drug for treating type 2 diabetes mellitus. (PubMed, Ann Med Surg (Lond)) - No abstract available

FDA event • Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

SGLT2 inhibitor use in the management of feline diabetes mellitus. (PubMed, J Vet Pharmacol Ther) - "Two SGLT2 inhibitors, namely bexagliflozin and velagliflozin, were recently FDA approved for the treatment of uncomplicated feline diabetes mellitus...Suitable candidates must have some residual β-cell function, as some endogenous insulin production is required to prevent ketosis. Appropriate patient selection and monitoring are necessary, and practitioners should be aware of serious complications such as euglycemic diabetic ketoacidosis."

Journal • Review • Cardiovascular • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Bexagliflozin as an Adjunct Therapy to Diet and Exercise to Improve Glycaemic Control in Adults with Type 2 Diabetes. (PubMed, touchREV Endocrinol) - "On 20 January 2023, bexagliflozin became the fifth orally administered sodium-glucose transporter 2 inhibitor to be approved by the US Food and Drug Administration for the treatment of T2D as an adjunct therapy to diet and exercise in the USA after dapagliflozin, canagliflozin, empagliflozin and ertugliflozin. This review aims to discuss the current evidence on the efficacy and safety of bexagliflozin, which provides an important alternative treatment option for patients with T2D."

Journal • Review • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Adipose Dysfunction, Imaging, Physiology, and Outcomes With Sodium Glucose Cotransporter 2 Inhibitor (SGLT2i) for Sleep Apnea: The ADIPOSA Study (clinicaltrials.gov) - P4 | N=164 | Recruiting | Sponsor: Yale University | Not yet recruiting ➔ Recruiting

Enrollment open • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Apnea • Sleep Disorder

Advancing Diabetes Care: Novel Drug Interventions in the Management and Control of Type 2 Diabetes Mellitus (ISPOR 2024) - " The study examines ongoing clinical trials evaluating the efficacy and safety of drugs like Cotadutide, Enavogliflozin, Retatrutide, ORMD-0801, and Imeglimin for T2DM, and reported data for at least 1 outcome of interest...Cotadutide, an insulinotropic drug, has shown promising results in improving glycemic control and weight loss in T2DM patients through delayed gastric emptying. Enavogliflozin had a slightly larger reduction in HbA1c levels (-0.99%) than Bexagliflozin...As monotherapy or adjunctive therapy (with metformin), it is found to be effective, has low risk of hypoglycemia, and enhances insulin action and sensitivity. Over the past decade, numerous glucose-lowering medications have been approved, requiring careful consideration of their risks and benefits. It is critical to establish the strongest evidence for improving glycemic control and reducing the risk of complications ."

Diabetes • Gastroenterology • Gastrointestinal Disorder • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Efficacy and safety of bexagliflozin compared with dapagliflozin as an adjunct to metformin in Chinese patients with type 2 diabetes mellitus: A 24-week, randomized, double-blind, active-controlled, phase 3 trial. (PubMed, J Diabetes) - "Bexagliflozin showed nearly identical effects and a similar safety profile to dapagliflozin when used in Chinese patients on metformin."

Clinical • Journal • P3 data • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Independent Pharmacy Cooperative (IPC) Secures Exclusive Distribution Rights to Independent Retail Pharmacies for BRENZAVVY (bexagliflozin) with TheracosBio Partnership (PRNewswire) - "Independent Pharmacy Cooperative (IPC)...proudly announces an exclusive distribution partnership with TheracosBio to make BRENZAVVY (bexagliflozin) accessible to its 6,000 member pharmacies. IPC, renowned for its commitment to supporting independent pharmacies, is set to be the first pharmaceutical wholesaler in the United States to carry and distribute BRENZAVVY....BRENZAVVY, an FDA-approved oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, presents a groundbreaking approach to diabetes care."

Licensing / partnership • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Bexagliflozin. (PubMed, Clin Diabetes) - No abstract available

Journal

Meta-analysis of risk of major adverse cardiovascular events in adults with type 2 diabetes treated with bexagliflozin. (PubMed, Diabetes Obes Metab) - "Bexagliflozin did not increase the risk of MACE in participants with T2D when compared with placebo or active control. Both the preapproval and postapproval thresholds for CV safety were met and bexagliflozin has been approved by the US Food and Drug Administration."

Adverse events • Journal • Retrospective data • Cardiovascular • Congestive Heart Failure • Diabetes • Heart Failure • Metabolic Disorders • Myocardial Infarction • Type 2 Diabetes Mellitus

A Meta-Analysis of the Efficacy and Safety of Bexagliflozin Versus Other Sodium-Glucose Cotransporter-2 Inhibitors (ASHP 2023) - No abstract available

Retrospective data

In brief: Empagliflozin (Jardiance) for chronic kidney disease. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Chronic Kidney Disease • Nephrology • Renal Disease

Bexagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, for improvement of glycemia in type 2 diabetes mellitus: a systematic review and meta-analysis. (PubMed, Expert Opin Pharmacother) - "The safety outcomes of bexagliflozin were consistent with the placebo arm. This study concluded that bexagliflozin seems to be a promising oral anti-diabetic drug for enhancing glycemic management in adult patients with T2DM."

Journal • Retrospective data • Review • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Bexagliflozin (Brenzavvy) - A fifth SGLT2 inhibitor for type 2 diabetes. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Review of the Safety and Efficacy of Bexagliflozin for the Management of Type 2 Diabetes. (PubMed, Ann Pharmacother) - "However, given lack of cardiovascular and renal outcome data, empagliflozin, dapagliflozin, or canagliflozin may be preferred. Bexagliflozin appears safe and effective as monotherapy and add-on pharmacological therapy for the treatment of T2D."

Journal • Review • Cardiovascular • Diabetes • Infectious Disease • Metabolic Disorders • Nephrology • Type 2 Diabetes Mellitus